Literature DB >> 34192897

Treatment and Outcomes of Patients With Ischemic Stroke During COVID-19: An Analysis From Get With The Guidelines-Stroke.

Pratyaksh K Srivastava1, Shuaiqi Zhang2, Ying Xian2,3, Hanzhang Xu4, Christine Rutan5, Heather M Alger5, Jason G Walchok5, Joseph H Williams5, James A de Lemos6, Marquita R Decker-Palmer7, Brooke Alhanti2, Mitchell S V Elkind8, Steve R Messé9, Eric E Smith10, Lee H Schwamm11, Gregg C Fonarow1,12.   

Abstract

BACKGROUND AND
PURPOSE: The coronavirus disease 2019 (COVID-19) pandemic has created challenges in the delivery of acute stroke care. In this study, we analyze the characteristics, evaluation, treatment, and in-hospital outcomes of patients presenting with acute ischemic stroke (AIS) pre-COVID-19 and during COVID-19.
METHODS: Get With The Guidelines-Stroke is a national registry of adults with stroke in the United States. Using this registry, we identified patients with a diagnosis of AIS before (n=39 113; November 1, 2019-February 3, 2020) and after (n=41 971; February 4, 2020-June 29, 2020) the first reported case of COVID-19 in the registry. Characteristics, treatment patterns, quality metrics, and in-hospital outcomes were compared between the 2 groups.
RESULTS: Stroke presentations decreased by an average of 15.3% per week in the during COVID-19 time period when compared with similar months in 2019. Compared with patients with AIS in the pre-COVID-19 era, patients in the COVID-19 time period had similar rates of intravenous alteplase and endovascular therapy, and similar door to computed tomography, door to needle, and door to endovascular therapy times. In adjusted models, inpatient mortality was similar between those presenting with AIS pre-COVID-19 and during COVID-19 (4.8% versus 5.2%; odds ratio, 1.05 [95% CI, 0.97-1.13]).
CONCLUSIONS: Among hospitals participating in Get With The Guidelines-Stroke, patients presenting with AIS during COVID-19 received, with few exceptions, similar quality care and experienced similar risk-adjusted outcomes when compared with patients with AIS presenting pre-COVID-19. These findings demonstrate that stroke care in the United States remains robust during the COVID-19 pandemic.

Entities:  

Keywords:  coronavirus; inpatient; ischemic stroke; pandemics; tomography

Year:  2021        PMID: 34192897     DOI: 10.1161/STROKEAHA.120.034414

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  3 in total

Review 1.  Global burden of the COVID-19 associated patient-related delay in emergency healthcare: a panel of systematic review and meta-analyses.

Authors:  Vahid Mogharab; Mahshid Ostovar; Jakub Ruszkowski; Syed Zohaib Maroof Hussain; Rajeev Shrestha; Uzair Yaqoob; Poorya Aryanpoor; Amir Mohammad Nikkhoo; Parasta Heidari; Athar Rasekh Jahromi; Esmaeil Rayatdoost; Anwar Ali; Farshid Javdani; Roohie Farzaneh; Aref Ghanaatpisheh; Seyed Reza Habibzadeh; Mahdi Foroughian; Sayyed Reza Ahmadi; Reza Akhavan; Bita Abbasi; Behzad Shahi; Arman Hakemi; Ehsan Bolvardi; Farhad Bagherian; Mahsa Motamed; Sina Taherzadeh Boroujeni; Sheida Jamalnia; Amir Mangouri; Maryam Paydar; Neda Mehrasa; Dorna Shirali; Francesco Sanmarchi; Ayesha Saeed; Narges Azari Jafari; Ali Babou; Navid Kalani; Naser Hatami
Journal:  Global Health       Date:  2022-06-08       Impact factor: 10.401

2.  The Spectrum of Acute Cerebrovascular Disease in Patients with COVID-19.

Authors:  Rachel Triay; Prabandh Buchhanolla; Alexas Gaudet; Victoria Winter; Alexandra Gaudet; Mehdi Faraji; Eduardo Gonzalez-Toledo; Harish Siddaiah; Hugo H Cuellar-Saenz; Steven Bailey; Vijayakumar Javalkar; Rosario Maria S Riel-Romero; Roger E Kelley; Felicity N E Gavins; Junaid Ansari
Journal:  Biomedicines       Date:  2022-02-13

3.  Stroke care during the COVID-19 pandemic: Case numbers, treatments, and mortality in two large German stroke registries.

Authors:  Alicia Brunssen; Viktoria Rücker; Peter Heuschmann; Jana Held; Peter Hermanek; Ansgar Berlis; Martin Hecht; Klaus Berger
Journal:  Front Neurol       Date:  2022-07-22       Impact factor: 4.086

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.